Company intelligence / Profile preview

Taili Biotechnology Shanghai Co Ltd.

Shanghai, Shanghai Shi, Chinatailai.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

Taili Biotechnology Shanghai Co Ltd. develops small molecules and antibody-drug conjugates targeting cancer and related indications. Its lead assets include Onapristone in Phase II for female genital neoplasms, TSN‑1611 targeting KRAS G12D in advanced solid tumors in Phase I/II, and TSN‑222 targeting P4HB x STING also in advanced solid tumors at Phase I/II. The company has at least six clinical trials ongoing or completed across its pipeline.

Therapeutic areas: OncologyPulmonologyGastroenterologyHematology
Modalities: Small molecule drugAntibody drug conjugate (ADC)
Industry: Biotech

Drug pipeline

3 assets

TSN222

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Taili Biotechnology Shanghai Co Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taili Biotechnology Shanghai Co Ltd..

Explore the full profile